(Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase
(sGC) stimulators for the treatment of serious and orphan diseases, today provided general corporate and pipeline updates and reported financial results for the second quarter of 2019.
The "Pulmonary Arterial Hypertension (PAH) Market By Drug Class (Prostacyclin And Prostacyclin Analogs, Soluble Guanylate Cyclase
(SGC) Stimulators, Endothelin Receptor Antagonists (ERA), Phosphodiesterase 5 (PDE-5)) And Segment Forecasts To 2025" report has been added to ResearchAndMarkets.com's offering.
The relaxation response curves to the extracts were also acquired in the presence of the nonspecific nitric oxide (NO) synthase inhibitor L-NAME (L-N(G)-nitroarginine methyl ester, 100 [micro]M) and soluble guanylate cyclase
inhibitor ODQ (1H-[1,2,4]-oxadiazolo[4,3-a] quinoxaline-1-one, 30 [micro]M).
Cyclerion Therapeutics announced its launch as an independent, publicly traded clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase
, or sGC, pharmacology to discover, develop and commercialize treatments for serious and orphan diseases.
The product is an orally administered central nervous system (CNS) penetrant soluble guanylate cyclase
(sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders.
But exploratory data suggested that riociguat, a soluble guanylate cyclase
stimulator, prevented disease progression in patients with early dcSSc, reported Oliver Distler, MD, head of the connective tissue diseases program at University Hospital Zurich.
and the .NO/cGMP signaling pathway.
In 1979, nitroprusside was shown to act via NO in bovine coronary artery, and it was demonstrated that NO activates guanylate cyclase
, resulting in vascular relaxation through cyclic guanosine monophosphate (cGMP) production (3).
It rapidly diffuses into the smooth muscle cells of the blood vessel and acts on soluble guanylate cyclase
. NO stimulates the soluble guanylate cyclase
to produce the second messenger cyclic 3',5' guanosine monophosphate from guanosine triphosphate (GTP).
In June 2018, we announced that we have entered into a research collaboration with Ironwood, focused on combining Ironwood's expertise in soluble guanylate cyclase
(sGC) and our proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new therapeutics for the treatment of certain ophthalmic conditions.
To verify if the cGMP modulates purinergic currents in Leydig cells, we repeated the ATP stimulation protocol in the presence of 300 [micro]M ODQ, a selective guanylate cyclase